← Back to Search

Monoclonal Antibodies

AL002 for Alzheimer's Disease

Phase 2
Waitlist Available
Led By TBD TBD
Research Sponsored by Alector Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests AL002, a drug for early Alzheimer's disease, in people who were part of an earlier study. It aims to check if AL002 is safe and effective over time.

Who is the study for?
This trial is for individuals with Early Alzheimer's Disease who completed the AL002-2 study, can consent to participate, and have a caregiver involved at least 10 hours weekly. Those unable to consent or discontinued from the previous study due to safety cannot join.
What is being tested?
The trial is testing the long-term effects of a drug called AL002 on safety, tolerability, and effectiveness in treating Early Alzheimer's Disease. It extends prior research by continuing treatment with this drug.
What are the potential side effects?
Specific side effects are not listed here but generally include any adverse reactions observed during the ongoing treatment with AL002. These could range from mild symptoms to more serious health concerns.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: AL002 Dose 3Experimental Treatment1 Intervention
AL002 every 4 weeks
Group II: AL002 Dose 2Experimental Treatment1 Intervention
AL002 every 4 weeks
Group III: AL002 Dose 1Experimental Treatment1 Intervention
AL002 every 4 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AL002
2021
Completed Phase 2
~450

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Alzheimer's Disease include cholinesterase inhibitors (e.g., donepezil, rivastigmine), which work by increasing levels of acetylcholine in the brain to help improve cognitive function, and NMDA receptor antagonists (e.g., memantine), which regulate glutamate activity to prevent excitotoxicity and neuronal damage. Monoclonal antibodies, such as those targeting amyloid plaques (e.g., aducanumab), aim to reduce amyloid-beta accumulation, potentially slowing disease progression. These treatments are crucial as they address different aspects of Alzheimer's pathology, offering symptomatic relief and potentially modifying disease progression, which is vital for improving the quality of life for patients.
Dupilumab for Atopic Dermatitis-From Clinical Trials to Molecular and Cellular Mechanisms.

Find a Location

Who is running the clinical trial?

Alector Inc.Lead Sponsor
10 Previous Clinical Trials
1,128 Total Patients Enrolled
AbbVieIndustry Sponsor
1,035 Previous Clinical Trials
522,856 Total Patients Enrolled
TBD TBDPrincipal Investigator
6 Previous Clinical Trials
1,467 Total Patients Enrolled

Media Library

AL002 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05744401 — Phase 2
Alzheimer's Disease Research Study Groups: AL002 Dose 1, AL002 Dose 2, AL002 Dose 3
Alzheimer's Disease Clinical Trial 2023: AL002 Highlights & Side Effects. Trial Name: NCT05744401 — Phase 2
AL002 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05744401 — Phase 2
~49 spots leftby Sep 2025